De-Risking the Future: What’s Holding Traditional Industry Back from Cannabis Investment?

Investment patterns in cannabis directly affect research funding, product development, and ultimately patient access to standardized, quality-controlled cannabis medicines. Traditional industry hesitancy limits the capital needed for rigorous clinical trials and pharmaceutical-grade product development that patients desperately need.

Traditional industries remain cautious about cannabis investment due to federal legal uncertainty, banking restrictions, and reputational concerns despite state-level legalization. This creates a capital gap that slows development of standardized cannabis products and limits research into therapeutic applications. The disconnect between state and federal law continues to constrain institutional investment that could accelerate medical cannabis research and product quality improvements.

“Until we have serious institutional investment flowing into cannabis research and development, patients will continue to navigate a market of inconsistent products with limited clinical data. This investment drought is a public health issue disguised as a business problem.”

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it:

{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “De-Risking the Future: What’s Holding Traditional Industry Back from Cannabis Investment?”, “url”: “https://businessofcannabis.com/de-risking-the-future-whats-holding-traditional-industry-back-from-cannabis-investment/”, “datePublished”: “2026-03-23T16:22:14Z”, “about”: “de risking future what s holding”}